Related Party Transactions (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Feb. 14, 2022 |
Nov. 08, 2021 |
Feb. 10, 2021 |
Mar. 30, 2020 |
Aug. 13, 2019 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Dec. 31, 2021 |
|
Value of common stock shares issued | $ 475,000 | |||||||||
Warrants exercise price | $ 0.4132 | $ 0.4132 | ||||||||
Fair value of warrants | $ 168,000 | $ 255,000 | ||||||||
Proceeds from issuance costs | $ 496,000 | |||||||||
Common stock held | 250,000 | 250,000 | ||||||||
Secured Convertible Promissory Note [Member] | ||||||||||
Increase in line of credit | 2,000,000.0 | |||||||||
Maximum borrowing capacity | $ 1,000,000.0 | $ 1,000,000.0 | ||||||||
Line of credit, expiry date | Feb. 14, 2024 | |||||||||
2022 Warrants [Member] | ||||||||||
Warrant to purchase share of common stock | 6,502,442 | 6,502,442 | ||||||||
Warrants exercise price | $ 0.71 | |||||||||
Warrants ecercise price | $ 0.88 | |||||||||
Common Stock [Member] | ||||||||||
Number of common stock shares issued | 242,000 | |||||||||
Value of common stock shares issued | ||||||||||
Proceeds from issuance costs | $ 10,000,000.0 | |||||||||
2020 Loan Agreement [Member] | ||||||||||
Line of credit, term | 18 months | |||||||||
Maximum borrowing capacity | $ 8,000,000.0 | $ 8,000,000.0 | $ 8,000,000.0 | |||||||
Warrant to purchase share of common stock | 3,670,663 | 3,670,663 | 3,670,663 | |||||||
Stock issued during period, shares | 28,500 | |||||||||
Line of credit facility, current borrowing capacity | $ 3,000,000.0 | |||||||||
Line of credit, expiry date | Mar. 30, 2023 | Mar. 30, 2023 | ||||||||
Line of credit facility, description | other indebtedness for money borrowed in excess of $100,000 becomes due and payable or can be declared due and payable prior to its due date or if indebtedness for money borrowed in excess of $25,000 is not paid when due; | |||||||||
2020 Loan Agreement [Member] | Warrant [Member] | ||||||||||
Warrants exercise price | $ 0.70 | |||||||||
Warrants ecercise price | $ 1.895 | |||||||||
2022 Secured Convertible Promissory Note and Security Agreement [Member] | ||||||||||
Line of credit, term | 12 months | |||||||||
Maximum borrowing capacity | $ 7,160,000 | |||||||||
Line of credit | 13,160,000 | |||||||||
Security Agreement [Member] | ||||||||||
Line of credit facility, description | if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date | |||||||||
Registration Rights Agreements [Member] | ||||||||||
Line of credit facility, description | AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 shares of our common stock held by Juvenescence and 3,248,246 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. | |||||||||
Juvenescence [Member] | ||||||||||
Line of credit facility | $ 10,160,000 | |||||||||
Warrant to purchase share of common stock | 6,502,442 | 6,502,442 | ||||||||
Reimbursement | $ 280,000 | |||||||||
Accounts payable | $ 69,000 | $ 69,000 | $ 70,000 | |||||||
Juvenescence [Member] | 2019 Loan Agreement [Member] | ||||||||||
Line of credit facility | $ 2,000,000.0 | |||||||||
Line of credit, term | 18 months | |||||||||
Increase in line of credit | $ 1,000,000.0 | $ 4,000,000.0 | ||||||||
Maximum borrowing capacity | 7,000,000.0 | $ 7,000,000.0 | ||||||||
Number of common stock shares issued | 19,000 | |||||||||
Value of common stock shares issued | $ 56,000 | |||||||||
Origination Fee | 160,000 | |||||||||
Warrant to purchase share of common stock | 150,000 | |||||||||
Warrants exercise price | $ 2.60 | |||||||||
Fair value of warrants | $ 236,000 | |||||||||
Juvenescence [Member] | 2022 Secured Convertible Promissory Note and Security Agreement [Member] | ||||||||||
Line of credit facility | $ 8,160,000 | |||||||||
Related party transaction description | (i) issuing additional shares in a transaction involving the sale, issuance, or potential issuance by the issuer of common stock (or securities convertible into common stock) equal to 20% or more of stock outstanding (determined as of the date of the particular transaction agreement) for less than the greater of book or market value of the Exchange listed common stock (the “20% Rule”) and (ii) issuing shares that will result in a change of control of the company (the “Change of Control Rule”). While the Exchange has not defined “change of control”, the Exchange considers any issuance of stock to be subject to the Change of Control Rule if the issuance of stock would result in a stockholder holding 50% or more of a company’s outstanding stock. The Secured Note contains a “19.9 % blocker” provision and a “change of control blocker” | |||||||||
Juvenescence Limited [Member] | Secured Convertible Promissory Note [Member] | ||||||||||
Line of credit | 10,160,000 | $ 10,160,000 | ||||||||
Line of credit facility, remaining borrowing capacity | 3,000,000.0 | 3,000,000.0 | ||||||||
Reverse Ratio [Member] | ||||||||||
Indebtedness | $ 15,000,000.0 | $ 15,000,000.0 |